Skip to content
RLX

RLX Technology, Inc.

RLX Technology, Inc. Q3 FY2026 earnings call

November 20, 2026 · fiscal period ended 2026-09

EPS · actual vs est

$0.02 / $0.03Miss -41.2%

Revenue · actual vs est

$168.3M / $260.2MMiss -35.3%
Ask about this call

Summary

Generated 2026-11-20

Management highlights

• Growth and market positioning

  • Management described the quarter as a strong start to 2026, driven by rapid international expansion and continued development of the mainland China business. The company emphasized localized strategies, user-focused product development, and partnerships with regional businesses.
  • Asia remains a core market where RLX aims to defend and strengthen its leading position; it entered two new markets in Southeast Asia and Europe during Q1.

• Europe and international expansion

  • Europe is a strategic priority, pursued through both organic growth and selective M&A. RLX is emphasizing locally tailored products, distribution partnerships, retail presence, and durable brand-building rather than rapid entry.
  • Integration with its European investee is based on strategic coordination, not interference in day-to-day operations. RLX is providing capital and global-platform support, including a new local warehouse to improve distribution and address prior capacity constraints.
  • Management said it is evaluating European acquisitions cautiously, prioritizing long-term strategic fit and synergy over immediate scale.

• Manufacturing and product portfolio

  • Nexus, the integrated smart manufacturing facility, is fully operational. Consolidating R&D, manufacturing, and commercial operations is intended to improve quality, efficiency, responsiveness, and control of proprietary technology.
  • Modern oral products are scaling, with capacity expansion and new distribution channels under development. Management expects overseas manufacturing infrastructure to support a significant increase in sales volume.
  • RLX has technical reserves for heated tobacco but sees current market conditions as unsuitable for major investment; e-vapor remains the principal near-term growth focus.

• Financial position and efficiency

  • Total financial assets were RMB 14.53 billion (approximately US$2.11 billion) at March 31, 2026, down from RMB 15.73 billion at year-end mainly because of dividend payments.
  • Receivable, inventory, and payable turnover days were 15, 32, and 49 days, respectively. Management highlighted disciplined cost control, supply-chain optimization, and strong working-capital management.
View in transcript ↓

Segment performance

The company did not disclose revenue or revenue contribution by product segment. Consolidated net revenue was RMB 1.59 billion, up 96.2% year over year and 38.9% quarter over quarter. Gross margin was 31.8%, compared with 28.6% a year earlier. Non-GAAP operating income rose 187.9% year over year to RMB 310.3 million, with a 19.6% non-GAAP operating margin versus 13.3%. Non-GAAP net income was RMB 357.3 million, up 41.4% year over year (the transcript also cites RMB 352.7 million for the prior-year period).

View in transcript ↓

Guidance

• Management did not provide quantified revenue, earnings, or margin guidance. It characterized Europe as a long-term growth opportunity but stressed selective investment and disciplined execution. • The company said it will focus near term on Asia, Europe, and other established international markets where it sees actionable growth opportunities; it has no immediate plan for a large-scale heated-tobacco launch. • Unannounced M&A opportunities are excluded from guidance, and the company will disclose developments when they are materialized. • Management expects the Chinese export-tax-rebate cancellation to have a minimal long-term effect on overall costs and margins. It said price pass-through may be used if needed; Q1 channel inventory front-loading is largely behind the company. • Overseas modern-oral manufacturing infrastructure, once fully established, is expected to support a significant uplift in sales volume.

View in transcript ↓

Risks

• Regulatory rules are evolving across markets. Compliance requirements, including UK vaping-product rules and licensing measures, may raise barriers and reshape competition; the company’s outlook depends in part on enforcement and implementation. • Q1 revenue was partly supported by downstream partners advancing orders ahead of China’s export tax rebate cancellation. Management said this temporary channel-inventory effect is largely past, so reported growth may not represent an equivalent increase in end-user demand. • The rebate change could affect costs and pricing. RLX expects the retail-price impact to be manageable and margins to be minimally affected over the long term, but the precise effect depends on value-chain pass-through. • European M&A and market expansion carry execution and uncertainty risks. Management is cautious and does not include unannounced transactions in its guidance. • The company has no U.S. operations. U.S. regulatory developments are being monitored, but the market is not an immediate operating focus. • Management noted the need to combat illegal products and described compliance, product quality, and regulatory uncertainty as central industry considerations.

View in transcript ↓

Q&A highlights

Q: How is RLX integrating its European investment, and what is its view of U.S. FDA developments and China policy changes? / A: Integration is strategic rather than hands-on: RLX relies on local expertise while providing capital and platform support, including a warehouse to improve distribution. It has no U.S. operations and is prioritizing Asia, Europe, and established markets; in China it supports enforcement against illegal products and is prepared for regulatory changes.

Q: What does the UK generational smoking ban mean for the European vape market? / A: Management sees the cigarette ban, while maintaining the legal purchase age for vaping at 18, as supportive of harm-reduction alternatives. Upcoming product and licensing rules may remove noncompliant competitors and benefit established compliant brands, though the company is building its presence carefully.

Q: What are RLX’s Europe investment and new-category plans? / A: The company is assessing M&A selectively and will not count unannounced deals in guidance. Modern oral products are being scaled, while heated tobacco has no near-term large-scale launch plan; e-vapor remains the immediate priority.

Q: How will cancellation of China’s export tax rebate affect costs and demand? / A: Partners brought orders forward in Q1 to prepare for the April change, but management said the volume shift was moderate and largely over, with little effect on organic end-user demand. RLX expects manageable retail pricing effects, will pass through costs if necessary, and anticipates minimal long-term margin impact.

Q: Where did RLX expand in Q1, and how does its approach differ by region? / A: It entered two new markets in Southeast Asia and Europe. In Asia it plans to leverage brand awareness and scale to extend its established model; in Europe it is adapting products and execution to local preferences and regulations.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.02$0.03-41.2%$0.02
Revenue$168.3M$260.2M-35.3%$145.2M

Transcript

November 20, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.